Verified Nov 2026
Other
·

Princeton, New Jersey
·
Since 2002
Taiho Oncology, Inc. is a clinical development and commercialization organization focused on oncology drugs, headquartered in Princeton, New Jersey, and founded in 2002. The company operates as the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd., with 200–500 employees and estimated revenue of $250–500M. It specializes in small-molecule anti-cancer agents targeting solid tumors and hematological malignancies, and recently completed FDA filing for zipalertinib in combination therapy for first-line lung cancer.
Taiho Oncology, Inc. at a glance
Revenue
$250-500M
Est. band
Employees
200-500
Founded
2002
Headquarters
Princeton, New Jersey
Industries
Automotive
Electric Vehicles
Medical
Overview
Taiho Oncology, Inc. is a clinical development and commercialization organization focused on oncology drugs, headquartered in Princeton, New Jersey, and founded in 2002. The company operates as the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd., with 200–500 employees and estimated revenue of $250–500M. It specializes in small-molecule anti-cancer agents targeting solid tumors and hematological malignancies, and recently completed FDA filing for zipalertinib in combination therapy for first-line lung cancer.
At a glance
Attribute | Detail |
|---|---|
Founded | 2002 |
Headquarters | Princeton, New Jersey |
Employees | 200-500 |
Revenue | $250-500M (estimated) |
What Taiho Oncology, Inc. makes
Taiho Oncology oversees clinical development of small-molecule anti-cancer agents from pre-clinical research through multiple trial phases, and manages commercialization and post-market activities for approved drugs in the U.S., Canada, and Europe.
Latest developments
2026-11-13 — Cullinan Partner Taiho Completes FDA Filing For Zipalertinib Combo In First-Line Lung Cancer (rttnews.com)
2026-04-28 — U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (taihooncology.com)
2026-04-27 — Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development (taihooncology.com)
2026-01-28 — Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer (taihooncology.com)
2025-11-20 — Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR E (taihooncology.com)
2025-07-09 — Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia (taihooncology.com)
Facilities
Taiho Oncology, Inc. is headquartered in Princeton, New Jersey. Public sources also reference these locations:
Princeton, New Jersey — taihooncology.com
Baar, Switzerland — taihooncology.com
Company details
The company operates as a U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., which is owned by Otsuka Holdings Co., Ltd., and maintains facilities in Princeton, New Jersey, and Baar, Switzerland. Taiho Oncology, Inc. was founded in 2002, has an estimated 200-500 employees, and is headquartered in Princeton, New Jersey.
Frequently asked questions
What does Taiho Oncology, Inc. do?
Taiho Oncology, Inc. is a clinical development and commercialization organization focused on oncology drugs, headquartered in Princeton, New Jersey, and founded in 2002. The company operates as the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd., with 200–500 employees and estimated revenue of $250–500M. It specializes in small-molecule anti-cancer agents targeting solid tumors and hematological malignancies, and recently completed FDA filing for zipalertinib in combination therapy for first-line lung cancer.
Where is Taiho Oncology, Inc. headquartered?
Taiho Oncology, Inc. is headquartered in Princeton, New Jersey (101 Carnegie Center Drive, Princeton, New Jersey, 08540).
When was Taiho Oncology, Inc. founded?
Taiho Oncology, Inc. was founded in 2002.
How big is Taiho Oncology, Inc.?
Taiho Oncology, Inc. has an estimated 200-500 employees, with revenue in the $250-500M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
